Disease progression, drug action and Parkinson's disease: Why time cannot be ignored

European Journal of Clinical Pharmacology

Volumn 64, Issue 2, 2008, Pages 207-216

  Holford, Nick ^a   Nutt, John G ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; NEUROPHARMACOLOGY; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; THEORETICAL MODEL;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; LEVODOPA; MODELS, BIOLOGICAL; PARKINSON DISEASE; TIME FACTORS;

EID: 39149100919     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0427-9     Document Type: Review

References (25)

1. Nutt JG, Holford NHG (1996) The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann Neurol 39:561-573
2. Chan PL, Nutt JG, Holford NH (2005) Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. J Pharmacokinet Pharmacodyn 32(3-4):307-331, Aug
3. Chan PL, Nutt JG, Holford NH (2005) Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 32(3-4):459-484, Aug
4. Chan PL, Nutt JG, Holford NH (2007) Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation. Pharm Res 24(4):791-802, Apr
5. Chan PLS, Nutt JG, Holford NHG (2004) Modeling the short and long duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. J Pharmacokinet Pharmacodyn 31(3):243-268
6. Holford NHG, Chan PL, Nutt JG, Kieburtz K, Shoulson I (2006) Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 33(3):281-311, Jun
7. Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6(6):429-453
8. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-356, Jul 19
9. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415-455, Dec
10. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276(7):374-379
11. Cotzias GE, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med 280(7):337-345
12. Fahn S, Calne DB (1978) Considerations in the management of parkinsonism. Neurology 28(1):5-7, Jan
13. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32(6):804-812, Dec
14. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 86(4):1398-1400, Feb
15. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1364-1371
16. The Parkinson Study Group (1989) DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46:1052-1060
17. Schulzer M, Mak E, Calne DB (1992) The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32(6):795-798
18. Fahn S (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 56(5):529-535
19. Jonsson EN, Sheiner LB (2002) More efficient clinical trials through use of scientific model-based statistical tests. Clin Pharmacol Ther 72(6):603-614, Dec
20. Hauser RA, Holford NHG (2002) Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 17(5):961-968
21. Nelson MV, Berchou RC, Lewitt PA, Kareti D, Kesaree N, Schlick P et al (1989) Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol 12(2):91-97
22. Nutt JG, Woodward WR, Carter JH, Gancher ST (1992) Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to On-Off phenomenon. Arch Neurol 49:1123-1130
23. Contin M, Riva R, Matinelli P, Baruzzi A (1992) Kinetic-dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's disease. Mov Disord 7(3):244-248
24. Contin M, Riva R, Martinelli P, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: Clinical application in Parkinson's disease. Neurology 43:367-371
25. Triggs EJ, Charles BG, Contin M, Martinelli P, Cortelli P, Riva R et al (1996) Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 51:59-67